Development and external validation of a new prognostic model for metastatic clear cell renal cell carcinoma: a preregistered analysis using data from randomised clinical trials in the checkpoint inhibitor era.
- DOI
- 10.1016/s1470-2045(26)00338-4
- Published
- 2026 Sep 9
- Container
- The Lancet. Oncology
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/s1470-2045-26-00338-4,
title = {Development and external validation of a new prognostic model for metastatic clear cell renal cell carcinoma: a preregistered analysis using data from randomised clinical trials in the checkpoint inhibitor era.},
author = {Richters A and Bond MJG and Westgeest HM and Özdemir BC and Damen JAA and Aben KKH and Bex A},
year = {2026},
journal = {The Lancet. Oncology},
doi = {10.1016/s1470-2045(26)00338-4},
url = {https://doi.org/10.1016/s1470-2045(26)00338-4}
}RIS
TY - JOUR TI - Development and external validation of a new prognostic model for metastatic clear cell renal cell carcinoma: a preregistered analysis using data from randomised clinical trials in the checkpoint inhibitor era. AU - Richters A AU - Bond MJG AU - Westgeest HM AU - Özdemir BC AU - Damen JAA AU - Aben KKH AU - Bex A PY - 2026 JO - The Lancet. Oncology DO - 10.1016/s1470-2045(26)00338-4 UR - https://doi.org/10.1016/s1470-2045(26)00338-4 ER -
APA
A, R., MJG, B., HM, W., BC, Ö., JAA, D., KKH, A., & A, B. (2026). Development and external validation of a new prognostic model for metastatic clear cell renal cell carcinoma: a preregistered analysis using data from randomised clinical trials in the checkpoint inhibitor era.. The Lancet. Oncology. https://doi.org/10.1016/s1470-2045(26)00338-4
Source records
- pubmed · retrieved 2026-09-25T23:28:18.192Z